Elsevier and Iktos launch AI-powered drug discovery database


Elsevier and Iktos have partnered to strengthen Elsevier’s chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos.

The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing the length and cost of early-stage drug discovery. New predictive models will be launched to support use cases including retrosynthesis, synthetic accessibility, and other reaction-based analyses.

Mirit Eldor, Managing Director, Life Sciences Solutions, Elsevier said: “Our mission is to support research and development (R&D) organisations in fueling innovation and drug discovery with industry-leading predictive algorithms trained on our high-quality data.”

Yann Gaston-Mathé, CEO, Iktos said: “We are committed to making our technology available to R&D organisations around the world to maximise the impact of AI on the productivity of drug discovery.”

In March 2023, Iktos raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions.

Megan Thomas, Multimedia Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free